Dr. DING Zhiming from Lexicon Pharmaceuticals Inc. visits GIBH

Dr. Ding Zhiming, director of Metabolism/Cardiology of Lexicon Pharmaceuticals Inc.Texas was invited to visit GIBH on October 18th, 2013.  Dr. Yu Daiguan from Drug Discovery Pipeline (DDP) of GIBH received the guest. Dr. Ding has been dedicating to drug development in cardiology and metabolism for the past 13 years. He has currently directed several projects, some of which are in pre-clinical studies and two others are in clinical Phase II. 

During his visit, Dr. Ding gave a seminar titled Inhibitors of Sodium-Glucose Cotransporters-Lowering Glucose by Insulin Independent Mechanism. At the seminar, Dr. Ding elaborated one of his ongoing projects. He began by firstly briefing the pathogenesis and treatment status for diabetes, then explicated the process and research results of sodium-glucose co-transporter (SGLT) inhibitor for treating diabetes, and finally highlighted the advantage of SGLT inhibitors for treatment of diabetes. Currently, the SGLT inhibitor is in clinical Phase II.  Dr. Ding’s presentation has aroused great interest among the audience. After the seminar, there was an in-depth discussion. 

Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery.  Its research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. Currently, the company has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.